• Johnson EF III, Wright JT. Management of hypertension in black populations. In: OparilS, WeberMA, eds. Hypertension. 2nd ed. Philadelphia, PA: WB Saunders Co; 2005:587595.
  • Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525541.
  • Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • Howard G, Anderson RT, Russell G, et al. Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol. 2000;10:214223.
  • Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:16361643.
  • Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393405.
  • Wright JT Jr, Douglas J. Optimal treatment of hypertension and cardiovascular risk reduction in African Americans: treatment approaches for outpatients. J Clin Hypertens (Greenwich). 2003;5(1 suppl 1):1825.
  • Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:24212431.
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • Julius S, Alderman MH, Beevers G, et al. The LIFE study. J Am Coll Cardiol. 2004;43:10471055.